| Comtan (entacapone) / Novartis, Orion Corp |
NCT03091868: Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics |
|
|
| Completed | 1 | 80 | Europe | Placebo oral capsule, Sinemet® 100/25, Comtan®, BIA 6-512 25 mg, BIA 6-512 100 mg | Bial - Portela C S.A. | Parkinson Disease | 02/05 | 02/05 | | |
NCT03094156: Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics |
|
|
| Completed | 1 | 39 | Europe | Placebo, BIA 6-512, Trans-resveratrol, Madopar® 250, Comtan® | Bial - Portela C S.A. | Parkinson Disease | 07/06 | 07/06 | | |
NCT01520727: A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects |
|
|
| Completed | 1 | 64 | Europe | BIA 9-1067, Entacapone, Placebo | Bial - Portela C S.A. | Parkinson Disease | 12/07 | 04/09 | | |
NCT01519284: Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic |
|
|
| Completed | 1 | 82 | Europe | BIA 9-1067 5 mg, OPC, Opicapone, Entacapone, Placebo, PLC, placebo, levodopa/carbidopa, BIA 9-1067 15 mg, BIA 9-1067 30 mg | Bial - Portela C S.A. | Parkinson Disease | 02/10 | 06/11 | | |
NCT02096601: A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients |
|
|
| Completed | 1 | 16 | RoW | LD/CD SC solution, ND0612, Entacapone | NeuroDerm Ltd., Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease | 03/15 | 03/15 | | |
NCT02058966: Pilot Study of Entacapone for Methamphetamine Abuse |
|
|
| Completed | 1 | 29 | US | Entacapone, Comtam, Methamphetamine, Desoxyn, Placebo | Oregon Health and Science University, Portland VA Medical Center | Methamphetamine Dependence | 06/16 | 06/16 | | |
NCT04006769: Entacapone Combination With Imatinib for Treatment of GIST |
|
|
| Completed | 1 | 5 | RoW | Entacapone, Comtan, Comtess, Imatinib Mesylate, Gleevec | Xiangya Hospital of Central South University | Gastrointestinal Stromal Tumor, Malignant | 08/22 | 08/22 | | |
NCT05976737: Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects |
|
|
| Not yet recruiting | 1 | 68 | NA | Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) | The Affiliated Hospital of Qingdao University | Healthy | 09/23 | 07/24 | | |
NCT06180720: Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects |
|
|
| Not yet recruiting | 1 | 36 | NA | Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) | The Affiliated Hospital of Qingdao University | Healthy | 01/24 | 11/24 | | |
NCT04246437: [18F]F-DOPA Imaging in Patients With Autonomic Failure |
|
|
| Recruiting | 1 | 40 | US | [18F]FDOPA, Carbidopa 200mg oral dose, Lodosyn, Entacapone 400mg oral dose, Comtan | Daniel Claassen | Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies | 02/25 | 02/25 | | |
